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Platelet-rich plasma (PRP) is an autologous 
product derived from whole blood through 
the process of gradient density centrifugation. 
PRP functions as a fibrin tissue adhesive with 
hemostatic and tissue sealing properties, but it 
differs from fibrin glue and other platelet-poor 
tissue adhesives because its platelets provide a 
unique ability to promote wound healing and 
enhance osteogenesis. PRP provides an immediate 
surgical hemostatic agent that is biocompatible, 
safe, and effective. PRP accelerates endothelial, 
epithelial, and epidermal regeneration, stimulates 
angiogenesis, enhances collagen synthesis, 
promotes soft tissue healing, decreases dermal 
scarring, enhances the hemostatic response to 
injury, and reverses the inhibition of wound 
healing caused by glucocorticoids. The high 
leukocyte concentration of PRP has an added 
antimicrobial effect. Since PRP is an autologous 
blood product, it carries no risk of transmitting 
infectious disease.
PRP has an extremely broad range of clinical 
healing applications in head and neck surgery, 
otolaryngology, cardiovascular surgery, burns and 
wound healing, oral and maxillofacial surgery, 
cosmetic surgery, and periodontics (Table 1). 
In addition to its effectiveness for patients with 
chronic non-healing wounds, it has also been used 
as an antiangiogenic agent and as a carrier for 
growth factors.
Clinical Applications of Platelet-Rich Plasma
Dear Readers
Dr Anila Rashid
Haematology & Transfusion Medicine
Hope you all had a great summer.
Year 2017s second issue of LABRAD is in your 
hands! This time it is non-thematic and has some 
useful articles like the broad clinical applications 
of platelet-rich plasma, clinical utility of plasma 
homocysteine, diagnostic tests available for 
Alkaptonuria and a discussion on soft tissue lesions. 
Another interesting article which might interest 
the pathologists is ‘Patient Based Quality Control: 
Hitting a Moving Target’ which discusses patient 
based QC procedures and how patient results can 
be utilized to monitor an analytical run and identify 
systematic errors.
Just to inform you all the 40th Annual Pakistan 
Association of Pathologists (PAP) Conference will 
be held from 14th to 16th December 2017 at Sindh 
Institute of Urology and Transplantation (SIUT), 
Karachi, Pakistan. The program will include pre-
conference workshops, state of the art lectures by 
local and foreign faculty, plenary sessions, oral and 
poster presentations. The local organizers are already 
hard at work putting together an exciting scientific 
program and we hope you will be a part of it. 
The Department of Pathology and Laboratory 
Medicine is committed to providing high 
quality diagnostic services for physicians across 
Pakistan. One of the goals of the Department is 
to update physicians throughout Pakistan about 
the advancement in laboratory sciences and the 
services available at the Clinical Laboratory, through 
Continuing Medical Education (CME) lectures 
across the country, laboratory updates and LABRAD. 
In order to keep the contents of LABRAD current 
and dynamic, readers are encouraged to send 
short articles on topics pertinent to healthcare and 
laboratories today. Since last year LABRAD is 
marked in the Institutional Repository and available 
on http://ecommons.aku.edu/pakistan. Readers from 
outside Aga Khan University now have the access 
current and previous issues of LABRAD from here 
and this has improved our newsletter readership.
I hope you enjoy this issue. 
Happy reading.
Lena
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Preparation
Numerous techniques have been described for the 
immediate preoperative preparation of autologous 
PRP, but most are variations on a standard theme. 
Blood is drawn from the patient and fractionated 
using centrifugation. The platelets are concentrated 
in the platelet rich plasma at levels generally six to 
eight times the baseline levels. The resultant PRP is 
stored at room temperature until needed, at which 
time 10,000 units of powdered bovine thrombin is 
mixed with 10 percent calcium chloride. Next, the 
PRP is drawn into a 10ml syringe. The thrombin/
calciumchloride mixture then is aspirated into a 
one ml syringe and both syringes are mounted in a 
mixing applicator. At the tip of the applicator, the 
two preparations are mixed to activate the PRP. 
Within five to 30 seconds, a gel is formed as the 
citrate is neutralized and the thrombin activates 
polymerization of the fibrin and degranulation of the 
platelets. The gel is then inserted into the surgical 
field as needed.
Most current methods of PRP preparation use 
calcium and bovine thrombin to initiate formation 
of PRP gel. The use of bovine thrombin has 
unfortunately been associated with the development 
of antibodies to human clotting factors V, XI, and 
thrombin, resulting in a risk of potentially life-
threatening coagulopathies. Several commercial 
systems are available for preparing PRP, including 
the Cobe Angel Whole Blood Separation System 
which also can produce fibrin glue (Cobe 
Cardiovascular, Inc., Arvada, Colorado) and the 
Sequire Platelet Concentrating System (PPAI 
Medical, Fort Myers, Florida). Most commercial 
PRP preparation systems are available for offi ce use 
by dental practitioners, podiatrists and wound care 
physicians. In comparison with previous methods 
that employed autotransfusion devices, current 
automated systems have shorter preparation times 
and require substantially less blood volume. 
Contraindications
Treatment with autologous PRP is generally 
considered safe in appropriately selected patients. 
Potential candidates for treatment with PRP should 
undergo a pretreatment hematologic evaluation 
to rule out potential coagulopathies and disorders 
of platelet function. Patients who are anemic and 
those with thrombocytopenia may be unsuitable 
candidates for treatment with PRP. Other potential 
contraindications include hemodynamic instability, 
severe hypovolemia, unstable angina, sepsis, and 
anticoagulant or fibrinolytic drug therapy. 
Conclusion
Autologous PRP is a relatively new biotechnology 
that has shown promise in the stimulation and 
acceleration of soft-tissue and bone healing. The 
application of PRP has been extended to many 
different fields, including orthopedics, sports injuries, 
dental and periodontal surgery, and cosmetic, plastic, 
cardiovascular, general and maxillofacial surgery. 
Few well-designed scientific studies of the clinical 
use of PRP are available. The exact mechanisms of 
action of the many components of PRP are not fully 
understood, and the ideal ratios of these components 
are unknown. In some circumstances, the cost of 
implementing this promising technology must be 
weighed against its benefits, and well-designed 
controlled clinical studies are needed to provide clear 
evidence of the capacity of PRP to improve patient 
outcomes.
Cosmetic Surgery 
Full and split-thickness skin grafts donor sites and recipient sites 
Skin flaps
 Bone grafts
Metal implants 
Tissue expansion 
Aesthetic Surgery (Face Lifts, liposuction, etc)
Oral and Maxillofacial Surgery
Mandibular reconstruction 
Alveolar cleft repair 
Oral-nasal fistulas
Otorhinolaryngology-Head and Neck Surgery 
Radical neck dissections 
Pectoralis major myocutaneous flaps
Facial fractures
Reconstructions
Neurosurgery 
Pituitary tumor removal 
Skull base tumor resection 
Intradural procedures involving tumor or release of tethered cords 
Dural tumors Acoustic neuroma excisions (dura tears during lami-
nectomy)
Table I: Clinical Applications of Platelet-Rich Plasma
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Rota Virus: Diagnosis & Prevention of 
Infection
Ms Syeda Kiran Zaidi
Clinical Microbiology
Rotavirus is the cause of mild to severe diarrhea in 
more than 18 million children under five years of age 
and is responsible for approximately 873,000 deaths 
per year. Due to compromised sanitation amenities 
and medical facilities available in the developing 
world, there is increased transmission and poor 
access to rehydration in patients suffering from 
severe vomiting and diarrhea due to rotavirus. It is 
also an important cause of nosocomial diarrhea.
Transmission and Reservoirs
Rotavirus is transmitted primarily through the fecal-
oral route, meaning an infected person must shed 
the virus through their stool and then a susceptible 
person must ingest it in order to cause an infection. 
Because rotaviruses grow and multiply in the 
intestinal villi, the gastrointestinal tract and stool 
serve as the reservoirs for rotavirus in infected 
humans. 
 
Signs and Symptoms
The most common symptoms include abdominal 
pain, vomiting, fever, and diarrhea. However, 
in some individuals rotavirus may also be 
asymptomatic. Although infants under three months 
of age may be infected, generally the first infection 
after three months is the most severe.
Diagnosis
The name rotavirus is derived from the Latin word 
“rota”, meaning “wheel”. Rotaviruses belong to the 
family Reoviridae and are nonenveloped, double-
shelled RNA viruses. The genome codes for six 
structural and six nonstructural proteins. The virus is 
stable in the environment. 
Laboratory diagnosis of rotavirus infection is usually 
performed by antigen detection, using enzyme 
immunoassay or latex agglutination techniques, 
which have a sensitivity and specificity above 90 per 
cent. Molecular techniques such as polyacrylamide 
gel electrophoresis (PAGE) and reverse transcription-
polymerase chain reaction (RT-PCR) are used 
to determine the RNA migration patterns and 
virus genotyping, respectively. The advantage of 
confirming a case of rotavirus diarrhoea 
Orthopedic/Spinal Surgery 
Total Hip Replacement 
Total Knee Replacement 
Scoliosis Repair 
Spinal Fusion
 All Open and Internal Reduction Fixation Operations 
Hand and Foot Surgery Bone Graft Surgery
Periodontal Surgery 
Dental implants 
Guided Bone Regeneration
Cardiothoracic Surgery 
Sternotomy Graft Conduit Sites 
Esophagogastrectomy
Eye-PRP
treatment of dormant ulcers (epithelial defects of the cornea that 
fail to heal)
 dry eye syndrome
ocular surface syndrome post Laser In Situ Keratomileusis 
(LASIK)
Surface reconstruction after corneal perforation associated with 
amniotic membrane transplantation.
General Surgery 
Recurrent Hernia Repair 
Anal Fistula 
Bariatric Surgery
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by laboratory testing is primarily epidemiological 
so that preventive measures may be initiated for the 
community at risk.
We, at Aga Khan University Hospital (AKUH) will 
be starting Rotavirus detection by Immuno Card 
STAT Rotavirus assay® (Meridian Bioscience, USA) 
which detects the presence of rotavirus antigen in 
stool through monoclonal antibodies directed against 
simian rotavirus strain (SA-11). It has specificity of 
95.8 per cent and sensitivity of 93.1 per cent and it 
gives result in just 10 minutes. Limit of detection in 
stool specimens is 1.8-3.7x108 rotavirus particles 
per test volume. The assay is not recommended 
on meconium (early neonatal) stools as their 
performance characteristics have not been evaluated. 
A positive result does not preclude the presence of 
other infective organisms. 
Prevention/Vaccines
Rotavirus is susceptible to strong disinfectants such 
as formalin and 95 per cent ethanol. Washing hands 
is not enough in preventing a rotavirus infection, as 
the viruses are relatively resistant to soap and water.
Currently there are two FDA approved vaccinations 
for rotavirus. RotaTeq was approved in 2006, 
and two years later in April of 2008 Rotarix was 
approved. Both vaccines are live attenuated viral 
vaccines taken orally in a scheduled series. RotaTeq 
is given in a three dose series at two, four, and six 
months of age, whereas Rotarix is given in a two 
dose series at four and six months.  Studies report an 
85-98 per cent efficacy rate against severe rotavirus 
infection, and a 74-87 per cent efficacy rate against 
rotavirus infection of any severity. 
Myasthenia gravis is the most common disorder of 
neuromuscular transmission. It can present at any 
age, but there tends to be a bimodal distribution to 
the age of onset with an early peak in the second 
and third decades with female predominance 
and a late peak in the sixth to eighth decade with 
male predominance. This autoimmune disease is 
caused by autoantibodies directed against muscle’s 
nicotinic acetylcholine receptor (AChRs) or muscle-
specific receptor tyrosine kinase (musk). There are 
two clinical forms of myasthenia gravis, ocular 
and generalized. In neonates, a transient form of 
myasthenia, called neonatal myasthenia gravis, can 
occur as a result of the trans placental passage of 
maternal antibodies that interfere with function of 
the neuromuscular junction but symptoms disappear 
after few weeks.
The cardinal feature of myasthenia gravis is 
fluctuating skeletal muscle weakness, in any 
skeletal muscle group. The weakness may fluctuate 
throughout the day, but it is most commonly worse 
later in the day or evening. More than 50 per cent 
of patients present with ocular symptoms of ptosis 
or diplopia while 15 per cent of patients present 
with bulbar symptoms like dysarthria, dysphagia 
and fatigable chewing. Less common presentations 
include isolated neck weakness, isolated respiratory 
muscle weakness, and distal limb weakness.
The diagnostic approach to myasthenia is focused 
on confirming the clinical diagnosis established 
by the history and typical examination findings. 
More reliable laboratory methods that aid in the 
confirmation are serologic tests for autoantibodies 
and electrophysiologic studies.
Anti- acetylcholine antibodies are used as a first 
Anti-Musk Antibodies for Seronegative 
Myasthenia Gravis
Dr Syed Bilal Hashmi
Chemical Pathology
Rota Virus: Electron microscopy (courtesy Google Images)
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line test to diagnosis myasthenia gravis and for 
distinguishing acquired disease (90 per cent 
positive) from congenital disease (negative). They 
are also used for monitoring disease progression 
or response to immunotherapy. The antibodies 
are present in 80-90 per cent of patients with 
myasthenia gravis.
Anti- musk antibodies are used for diagnosis of 
autoimmune myasthenia gravis in patients with new 
onset acquired myasthenia gravis evident clinically 
and electrophysiological but negative first-line 
serological tests, i.e. autoantibodies against 
AChRs. These autoantibodies are present in half 
of seronegative myasthenia gravis patients. It also 
helps in distinguishing autoimmune from congenital 
Role of Homocysteine in Atherosclerosis
Atherosclerosis is a pathologic process caused by 
the buildup of plaque/ fatty material on the inside 
of blood vessels leading to decreased blood flow 
commonly affecting the coronary, cerebral and 
peripheral arteries. Recently, there is increased 
evidence that raised homocysteine levels in blood 
are an independent cause of atherosclerotic vascular 
disease and recurrent venous thromboembolism. 
Homocysteine is an intermediary amino acid 
produced during the conversion of methionine to 
cysteine (Figure 1). Homocysteine has primary
myasthenia gravis, diagnosing ocular myasthenia 
gravis and monitoring clinical course and response 
to immunomodulatory treatment of a myasthenia 
gravis patient. 
The diagnosis of myasthenia gravis 
in immunosuppressed or patients on 
immunosuppressive drugs should be made with 
caution because these autoantibodies may be falsely 
low in such cases. Also 10 per cent of patients with 
acquired, presumably immune-mediated myasthenia 
gravis do not have detectable serum autoantibodies 
to AChR or MuSK. In these seronegative patients, 
the diagnosis is based on the clinical presentation, 
the response to cholinesterase inhibitors and 
electrophysiological findings.
atherogenic and prothrombotic properties. 
Homocysteine-induced vascular injury include 
intimal thickening, elastic lamina disruption, smooth 
muscle hypertrophy, marked platelet accumulation, 
and the formation of platelet-enriched occlusive 
thrombi. Homocysteine causes vascular injury by 
following mechanisms:
l Increased leukocyte recruitment
l increased smooth muscle proliferation and   
 collagen synthesis
l attenuation of endothelial cell tissue 
 plasminogen activator binding sites
l activation of factor VIIa and V
l inhibition of protein C and heparin sulfate
l increased blood viscosity, and decreased 
 endothelial antithrombotic activity due to 
 changes in thrombomodulin function
l increased oxidative stress via production of free 
 radicals
l increased platelet accumulation
l decreased Nitric oxide production leading to 
 impaired endothelial vasodilation.
Causes of Hyperhomocytenemia
An inadequate intake of B vitamins, as well as 
genetic factors that affect the body’s absorption and 
use of folic acid, can lead to elevated homocysteine 
levels. Homocysteine can be elevated in the 
Clinical Utility of Plasma Homocysteine 
Salima Ratani and Hafsa Majid 
Microbiology and Chemical Pathology
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range” that was determined from patient data. For 
control limits, Hoffman and Waid used the 95 per 
cent confidence limits for the stable patient mean. 
The AON can be done on relatively small sample 
like significant analytic error could be detected by 
averaging as few as ten consecutive values. 
For establishing AON the laboratory needs to decide, 
outliers to be excluded (especially for average), age 
limits (eg 18 to 70yrs for serum creatinine), define 
location of sample received from (eg dialysis unit, 
surgical unit, outpatients etc) and if multiple results per 
patient would be allowed or only one result per patient 
will be taken 
in calculation 
of averages. 
An example 
of AON graph 
for plasma 
glucose is 
shown in 
figure 1.
Patient Based Quality Control: Hitting a 
Moving Target
Dr Hafsa Majid
Chemical Pathology
Clinical laboratories are required to ensure accuracy 
of every result reported; for that purpose since long 
quality control materials are used. The CLIA have 
recommended that minimum two level controls should 
be run each day. The question arises whether with 
increasing volumes this frequency of running controls 
would be enough for high volume laboratories? On 
the other hand if the controls run per day are increased 
it will directly impact the cost. As a solution patients’ 
data can be utilized (‘patient-based quality control’) 
that monitors in real time the average patient value for 
any given analyte. The patients’ data can be used in two 
ways for assessing systemic errors described below.
Average of Normals’ (AON)
The AON method of quality control was first 
described by Hoffman & Waid in 1965. In AON, 
an error condition is signaled in an analytic process 
whenever the average of selected consecutive 
patient data is beyond the control limits established 
for the average of the patient population. Patient 
results included if they were within a “normal 
following conditions: 
l Thermolabile variant of MTHFR (Methylene 
 Tetra Hydrofolate Reductase) having low 
 enzyme activity
l Intracellular cobalamin defects
l Vitamin B6 deficiency
l Vitamin B12 deficiency
l Folic acid deficiency
Plasma and urine concentrations of homocysteine 
are severely elevated in a rare autosomal 
recessive disorder; homocysteinuria or severe 
hyperhomocytenemia. It is clinically manifested 
as developmental delay, ocular abnormalities, 
thromboembolic disease and even osteoporosis.
Laboratory Diagnosis 
75 to 85 per cent of homocysteine is protein bound, 
15 to 25 per cent is acid-soluble free forms. Plasma 
homocysteine levels normally are between 5-12 
µmol/L and levels  >100 µmol/L are considered 
as severely high. An oral methionine challenge 
(100 mg/kg) can be given to patients suspected of 
hyperhomocysteinemia who have normal fasting 
homocysteine levels. It is more useful for patients 
with cystathionine-beta-synthase deficiency than 
for those with MTHFR reductase deficiency. The 
homocysteine concentration is measured on fasting 
plasma samples before the methionine challenge 
and four and eight hours afterward.  The prognostic 
significance of the oral methionine challenge is 
uncertain. Correcting nutritional inadequacies will 
lower homocysteine levels. A diet rich in fruits, 
vegetables, and low-fat dairy products and low in 
saturated and total fat also can lower fasting serum 
homocysteine levels. Trials in primary and secondary 
prevention of the disease show that adequate intake 
of vitamin B complex, whether in diet or from 
supplements, prevents homocysteine-associated 
vascular disease. 
Figure 1: Inpatients’ Average of Normal chart for plasma glucose for the 
month of December.
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Patient Moving Averages (PMA)
Moving averages is a simple arithmetic mean of 
predefined consecutive patient results. The number 
of consecutive results to be included are decided, 
average calculated and with each new patient result 
the window moves by one patient result while 
the oldest value drops out of view. The mean is 
recalculated and data point plotted on a Levey-
Jennings chart.
In PMA calculation protocol two parameters need to 
be defined: 
 a. The size of the error you wish to detect   
  require control limits and n (number of 
  consecutive results that need to be averaged).  
  To detect 
  i. Large error; wider limits and large ‘n’
  ii. Even a small error; narrow limits and  
   small ‘n’. Also It is easier to detect a 
   small shift for analytes  that have a 
   narrow range (Na, Cl), than for highly  
   variable analytes (Triglycerides)
 b. Truncation limits: values that need to be  
  excluded from the mean calculation, eg days  
  when patient mix or volumes changes 
  drastically like on weekend patients’ 
  volumes decrease so it can affect PMA of 
  that day and if multiple samples are received 
  from a camp for chronic kidney disease or 
  hepatitis C patients can affect PMA for 
  creatinine of LFTS. Such results should be 
  excluded from calculations.
In monitoring AON or PMA the goal is to monitor 
the process and not the patients. In the absence of 
systematic error, the mean patient value doesn’t 
deviate significantly from the historic patient mean. 
A mean exceeding predefined control limits thus 
indicates the possible presence of a systematic error. 
These tools are more useful when data is collected 
regularly (every week or every month), and for 
relatively high-volume tests (n=>50 samples per 
day).
Selection of Analytes for PMA Monitoring
Not every analyte is amenable to PMA monitoring. 
If daily test volume are less than the pre-decided 
‘n’ for PMA calculation then there is no point in 
monitoring PMA. It is not suitable for analytes 
with great variability eg CK, LD. The PMA 
monitoring will not be effective for analytes such 
as troponin, as it is undetectable in most patients 
so for it monitoring moving median will be more 
practical. 
Advantages of PMA Monitoring 
Appropriately designed and implemented moving 
averages protocols can detect a systematic error 
hours before your next quality control run and will 
also decrease the frequency of control runs per day. 
The real challenge in setting up moving averages 
monitoring is defining your own protocol and taking 
corrective action to control the systematic error 
identified.  
Alkaptonuria is a rare inherited metabolic disorder 
(IMD) due to deficiency of the hepatic enzyme 
Homogentisate 1,2-dioxygenase involved in tyrosine 
degradation pathway forming an intermediate 
metabolite homogentisic acid (HGA) and its 
oxidative products in various connective tissue. The 
true incidence of Alkaptonuria varies from 1:500,000 
to 25:500,000, prevalence is higher in Middle 
Eastern and Asian countries compared to western 
countries owing to the high cousin marriage rate.
Diagnosing Alkaptonuria: A Rare Inherited 
Metabolic Disease
Dr Yusra Zaidi
Chemical Pathology
Life expectancy is not affected in patients with 
Alkaptonuria, but the quality of life is significant 
affected due to accumulation of HGA in the 
tissues giving rise to ochronosis (yellow to brown 
discoloration) in tissues especially cartilage, tendons, 
ligaments, at times even bone and makes them 
brittle, weak and susceptible to rupture.
Affected individuals may have dark urine or urine 
that turns black when exposed to air. However, 
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Recently Described Soft Tissue Lesions: An 
Update
Qurratulain Chundriger and Nasir Ud Din
Histopathology
Soft tissue pathology is a rapidly changing 
subspecialty. Several soft tissue lesions have been 
recently described in the medical literature. Some 
are recently recognized, hence often underdiagnosed 
because of limited knowledge whereas others have 
been recognized for some time but can be viewed 
afresh in light of emerging molecular data. Here we 
discuss six of these recently described soft tissue 
tumours. 
Angiofibroma of Soft Tissue
In 2012, Mariño-Enriquez and Fletcher described 37 
cases of a distinctive benign fibrovascular tumour 
that arose most commonly as a soft tissue mass of 
the extremities and was characterized by a specific 
translocation t(5;8) (p15;q13). These lesions were 
named as Angiofibroma of soft tissue. They are 
slow growing tumours of the subcutis or deep soft 
tissue most commonly arising in the extremities of 
adults (median age 49 years) with a slight female 
predominance (2:1). Most are well-circumscribed 
lesions with a median size of 3.5 cm (range: 1.2– 
12.0 cm).
Histologically, these tumours characterized by a 
proliferation of uniform bland spindle cells with 
present in a variably myxoid or collagenous stroma. 
The cells have ovoid nuclei and inconspicuous 
cytoplasm. A prominent network of small thin-walled 
and finely branched blood vessels is seen. Epithelial 
membrane antigen (EMA) is positive in nearly 
this change may not occur for several hours after 
urination and often goes unnoticed.  Most common 
symptomatic presentation is arthritis especially in 
the spine and large joints (Ochronotic arthropathy), 
beginning early and progressing more rapidly in 
males than females. Additional symptoms that 
are seen less often include kidney stones, prostate 
stones and heart disease due to accumulation of 
HGA within the aortic or mitral valve.
Patients are diagnosed with Alkaptonuria based on 
increased HGA excretion, evident by presence of 
peak on urine organic acid chromatogram detected 
by gas chromatography-mass spectrometry 
analysis; as shown in figure 1. From 2013 till to 
date the Biochemical Genetics Laboratory of our 
section has reported nine cases of Alkaptonuria. 
All patients were diagnosed based on marked 
peaks of Homogentisic acid on urine organic 
acid. Male to female ratio was 2:1. Most common 
age of presentation was in third, fourth and fifth 
decade of life while two cases presented within 
first year of their birth.
Standard Treatment for Alkaptonuria includes 
symptomatic treatment for pain using anti-
inflammatory drugs or narcotics may also be 
prescribed, if needed. Dietary protein restrictions 
are advised and vitamin C is prescribed, 
which prevent accumulation and deposition 
of HGA. Recently a drug, Nitisone is (a drug 
for Tyrosinemia) is under study for use in 
Alkaptonuria. It is shown to prevent significant 
accumulation of homogentisic acid but further 
research is needed to understand its safety and 
effectiveness in long term usage. Figure 1: Chromatogram showing Homogentisic Acid Peak (marked with 
red arrow).
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half of cases, usually only in scattered cells but 
rarely diffusely. Focal staining for desmin, smooth 
muscle actin (SMA), or CD34 may be seen in a 
subset of cases, but S100 protein is negative. Main 
differential diagnoses include Myxoid Liposarcoma, 
Solitary Fibrous Tumour, Low grade fibromyxoid 
Sarcoma, Low grade myxofibrosarcoma and cellular 
angiofibroma. Angiofibroma of soft tissue is a benign 
tumour, but may occasionally recur locally. 
Fibrosarcoma-like Lipomatous Neoplasm
In 2013, Deyrup and colleagues revisited the concept 
of “spindle cell liposarcoma”. Based on their analysis 
of previous publications on this topic, this term in 
their opinion actually represents a heterogeneous 
group of tumours, including variants of well 
differentiated liposarcoma, myxoid liposarcoma, and 
even spindle cell lipoma. Excluding those entities by 
molecular analysis, they described 12 cases of a low 
grade adipocytic neoplasm with prominent spindle 
cell component which they termed “fibrosarcoma-
like lipomatous neoplasm” . Most of these tumours 
arise in adults (mean age: 50 years). These tumours 
present as superficial or deep soft tissue masses with 
a wide size range (mean: 7.5 cm) arising in the groin 
and para-testicular region, as well as the buttock, 
thigh, flank, and shoulder. 
Key histologic features include a uniform fibroblast-
like spindle cells arranged in parallel bundles, 
myxoid background with arborizing thin vessels, 
wide range of lipoblasts lacking significant atypia, 
including signet ring and spindled univacuolated/
bivacuolated cells. Univacuolated (“ice cream cone”) 
and bivacuolated (“hourglass”) spindled lipoblasts 
are often seen in fibrosarcoma-like lipomatous 
neoplasm. Main Differential Diagnoses include Well-
differentiated liposarcoma/atypical lipomatous tumor 
(WDL/ALT), Myxoid liposarcoma and Spindle cell 
lipoma. Fortunately, molecular analysis can usually 
easily exclude these possibilities.  
No recurrence or metastasis was identified in any 
of these patients (mean follow-up time: 68 months; 
range 9 month to 20 years), suggesting that perhaps 
“liposarcoma” is not an appropriate term for this 
tumor, based on current data. 
Biphenotypic Sinonasal Sarcoma
Sarcomas arising in the sinonasal region are in 
general very rare. Biphenotypic sinonasal sarcoma 
a.k.a low-grade sinonasal sarcoma with neural 
and myogenic features is a recently described 
entity based on review of sinonasal sarcomas from 
several decades of cases and consults. The clinical 
presentation of biphenotypic sarcoma is features 
of sinusitis, difficulty in breathing, facial pressure, 
congestion, and, rarely, facial pain. The age range is 
24 to 85 years (mean: 52 years), and there is female 
predominance in the original series (21 women, 7 
men). The tumour most commonly affects multiple 
sites, including the nasal cavity proper (54 per cent) 
and ethmoid sinus (57 per cent); extension into the 
orbit and cribriform plate are common. The key 
histologic features include poor circumscription, 
infiltrative growth of highly cellular, bland spindle 
cells, in vague “herringbone” pattern, without atypia 
or frequent mitoses, along with benign proliferation 
of respiratory epithelium with variable admixture 
with tumor cells. These tumours show dual positivity 
for S100 (neural marker) and Smooth muscle actin 
and muscle specific actin (muscle markers), thus 
called biphenotypic. A recent study by Wang and 
colleagues found PAX3 rearrangement by FISH in 
96 per cent of these cases (n=25); 79 per cent of 
these cases were positive for PAX3-MAML3 fusion 
Figure 1. Angiofibroma of soft tissue with chicken wire type vessels, 
collagenous stroma and bland spindle cells
Figure 2. Fibrosarcoma-like lipomatous neoplasm exhibiting a wide 
ranging of adipocytic differentiation (uni and bivacuolated lipoblasts)
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Prognosis may be good if the tumour can be 
completely removed; however, metastases are 
common (over 50 per cent), often to liver and lymph 
nodes. 
Superficial CD34 Positive Fibroblastic Tumour
In 2013, Carter and colleagues described 18 cases 
of a tumour with borderline malignant potential, 
having unique characteristics i.e. striking nuclear 
pleomorphism, paradoxically rare mitotic activity, 
indolent behavior, and diffuse CD34 expression. 
They termed it as “Superficial CD34 positive 
fibroblastic tumour”. Awareness of this entity is 
important, as there is a tendency for overdiagnosis as 
a pleomorphic sarcoma in light of the nuclear atypia, 
even though most cases do not recur or metastasize. 
The tumour presents in adults as a slow-growing 
supra-fascial mass with a mean size of 4.1 cm, most 
commonly in the lower extremity. Histologically 
it shows striking pleomorphism but low mitotic 
rate (<1 per 50 HPFs). The cells are spindled to 
epithelioid with abundant eosinophilic often granular 
cytoplasm and are arranged into hypercellular 
sheets or fascicles. Most tumour cells display 
marked nuclear pleomorphism with hyperchromasia 
and multiple large inclusion-like nucleoli as 
well as cytoplasmic nuclear pseudoinclusions. 
Xanthomatous foamy tumour cells are commonly 
seen, and mixed inflammation is often present. There 
is diffuse strong CD34 expression (always), focal 
cytokeratin expression (often). FLI-1, ERG, S100 
protein, desmin, smooth muscle actin, and TP53 
are all negative, Ki-67 proliferative index is less 
than one per cent, and nuclear INI-1 (SMARCB1) 
expression is retained. Differential diagnoses 
include Undifferentiated pleomorphic sarcoma, 
Myxofibrosarcoma, Atypical fibroxanthoma, 
Myxoinflammatory fibroblastic sarcoma and 
Pleomorphic hyalinizing angiectactic tumor.
by RT-PCR. Main Differential Diagnoses include 
Fibrosarcoma, Malignant peripheral nerve sheath 
tumour and Monophasic Synovial sarcoma.  Local 
recurrence is common, but metastases or mortality 
from disease have not yet been reported. 
Malignant Gastrointestinal Neuroectodermal 
Tumour
Malignant gastrointestinal neuroectodermal 
tumor (GNET) is a rare, aggressive tumour of 
the gastrointestinal (GI) tract that has previously 
been called as “clear cell sarcoma-like tumour 
of the GI tract with osteoclast-like giant cells”. 
Stockman and colleagues proposed this name after 
a review of 16 cases which showed histologic, 
immunohistochemical, and molecular findings 
similar to Clear cell sarcoma of soft tissue, but 
with distinct differences, including no evidence 
of melanocytic differentiation. GNET typically 
arises in young to middle aged adults and most 
often involves the small intestine. The tumour is 
typically centered within the wall of the bowel, 
with secondary involvement of the mucosa and 
serosa. Histologically, the tumours grow in solid 
sheets, pseudopapillary formations and alveolar 
formations, generally without the well-formed 
nests that characterize soft tissue-type clear cell 
sarcoma. The cells are epithelioid to polygonal 
with variable amount of eosinophilic cytoplasm 
and vesicular nuclei with chromatin margination 
and scattered intranuclear cytoplasmic inclusions. 
The tumour cells are positive for S100, SOX10 
and neuroendocrine markers; however, markers of 
melanocytic differentiation, including Melan A and 
HMB45 are negative. These tumours show EWSR1 
rearrangement with numerous fusion partners. Main 
differential diagnoses include GIST, monophasic 
synovial sarcoma, melanoma, soft tissue clear cell 
sarcoma and and Epithelioid Malignant Peripheral 
Nerve Sheath tumour.
Figure 3. Biphenotypic sinonasal sarcoma showing fascicles of bland 
spindle cells. Figure 4. Polygonal cells with a pseudovascular spaces seen in GNET.
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predominantly neutrophils or lymphocytes is seen 
intermixed with tumour cells. Immunohistochemical 
stain for ALK protein shows positivity in unique 
nuclear membrane or perinuclear cytoplasmic 
pattern.  The diagnosis of EIMS may be very 
challenging given its rarity and lack of histologic 
similarity to typical IMT. Main differential diagnoses 
include Anaplastic large cell lymphoma (ALCL), 
Epithelioid leiomyosarcoma,  Rhabdomyosarcoma 
and Dedifferentiated liposarcoma. 
Conclusion
Owing to rapidly updating classification schemes 
in histopathology, the pathologists as well as the 
clinicians should be able to update their knowledge, 
in order to be able to better understand the tumour 
biology and therefore avoid over or under treatment 
of patients.
Epithelioid Inflammatory Myofibroblastic 
Sarcoma
Inflammatory myofibroblastic tumour (IMT) is a 
mesenchymal tumour of intermediate malignant 
potential composed of spindled myofibroblasts with 
admixed inflammation.  A rare epithelioid variant 
of IMT with distinctive nuclear membrane or 
perinuclear ALK staining was recently described and 
termed “epithelioid inflammatory myofibroblastic 
sarcoma” (EIMS) in light of its more aggressive 
behavior than conventional IMT. EIMS has a 
marked male predominance and wide age range (7 
months–63 years, median 39 years. These tumours 
are almost exclusively found in the abdominal 
cavity. The lesions range in size from 8 to 26 cm. 
Histologically the tumors show epithelioid cells with 
vesicular nuclei and prominent nucleoli present in 
a myxoid stroma. Inflammatory infiltrate of either 
Figure 5. Large polygonal cells with glassy cytoplasm and prominent 
nucleoli and rare mitosis; features seen in Superficial CD34 positive 
fibroblastic tumour.
Figure 6. Scattered epithelioid cells with abundant eosinophilic 
cytoplasm, vesicular nuclei containing prominent nucleoli seen in 
epithelioid inflammatory myofibroblastic sarcoma.
Diabetes Mellitus (DM) is one of the most widespread 
diseases with an increasing incidence globally. 
Statistically, Pakistan is ranked seventh among the 
list of countries with a reportedly high prevalence 
of DM making it a major public health concern. In 
order to promote Diabetes care and management 
every year the American Diabetes Association 
(ADA) releases the Standards of Medical Care in 
Diabetes. This document is the output of the ADA’s 
multidisciplinary professional practice committee 
that systematically searches MEDLINE to revise 
or clarify recommendations. Feedback from the 
larger clinical community is also incorporated. The 
recommendations are summarized as follows:
A Snapshot of the Standards of Medical Care 
-2017: American Diabetes Association Guidelines 
Dr Sibtain Ahmed
Chemical Pathology 
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Definitions
Diagnostic 
Criteria
Age at 
Diagnosis
Diabetes Mellitus 
Type 1
Diabetes due to 
autoimmune B-cell 
destruction, usually 
leading to absolute 
insulin deficiency
Diabetes Mellitus 
Type 2
Diabetes due to a 
progressive loss 
of B-cell insulin 
secretion frequently 
on the background 
of insulin resistance
Latent Auto 
Immune Diabetes of 
Adults (LADA)
LADA is defined as 
initially non-insulin 
requiring diabetes 
diagnosed in adults 
with antibodies to 
GAD - glutamic acid 
decarboxylase.
To discriminate LADA 
from type I and/or type 
II DM, diagnosis of 
LADA has been based 
on three criteria as given 
by The Immunology of 
Diabetes Society:
•  Adult age of onset  
(> 30 years of age);
•  Presence of at least 
one circulating autoan-
tibodies (GADA/ICA/
IAA/IA-2); and
•   Initial insulin 
independence (for the 
first six months).
Usually age ≥ 30 yrs
Maturity Onset 
Diabetes of the Young 
(MODY)
MODY is an inherited 
form of diabetes 
mellitus. It is caused by 
caused by mutations in 
an autosomal dominant 
gene disrupting insulin 
production 
Individuals with a 
strong family history 
of diabetes, presenting 
from the second to the 
fifth decade, should 
be evaluated further 
through sequencing 
of the suspected gene 
(HNF1A, GCK etc) and 
detecting a mutation.
< 25 years
Gestational Diabetes 
Mellitus (GDM)
Diabetes diagnosed 
in the second or third 
trimester of pregnancy 
that is not clearly overt 
diabetes
Perform a 75-g OGTT
The diagnosis of GDM 
is made when any of 
the following plasma 
glucose values are met 
or exceeded:
•  Fasting: 92 mg/dL 
(5.1 mmol/L) 
•  1 h: 180 mg/dL (10.0 
mmol/L) 
•  2 h: 153 mg/dL (8.5 
mmol/L) 
> 25 years
A1C ≥6.5%.
OR
FPG ≥126 mg/dL (7.0 mmol/L).
OR
2-h PG ≥200 mg/dL (11.1 mmol/L) 
during an OGTT.
OR
Random glucose ≥200 mg/dL (11.1 
mmol/L).
Most commonly in 
childhood
Most commonly in 
adults
Criteria For Screening For Diabetes In Asymp-
tomatic Adults
Testing should be considered in overweight or obese 
(BMI ≥25 kg/m2 or ≥23 kg/m2 in Asian Americans) 
adults who have one or more of the following risk 
factors: 
l A1C ≥5.7% (39 mmol/mol), impaired glucose  
 tolerance, or impaired fasting glucose on previ 
 ous testing
l First-degree relative with diabetes
l High-risk race/ethnicity (e.g., African American, 
 Latino, NativeAmerican, Asian American, 
 Pacific Islander)
l  Women who were diagnosed with GDM
l  History of CVD
l  Hypertension (≥140/90 mmHg or on therapy for 
 hypertension)
l  HDL cholesterol level <35 mg/dL (0.90 
 mmol/L) and/or a triglyceride level >250 mg/dL 
 (2.82 mmol/L)
l  Women with polycystic ovary syndrome
l  Physical inactivity
l  Other clinical conditions associated with insulin 
 resistance (e.g. severe obesity, acanthosis 
 nigricans)
When to Screen? For all patients, testing should 
begin at age 45 years.
How often to screen? If results are normal, testing 
should be repeated at a minimum of 3-year intervals, 
with consideration of more frequent testing depend-
ing on initial results (e.g., those with prediabetes 
should be tested yearly) and risk status.
Criteria For Screening For Diabetes In Asymp-
tomatic Children 
Overweight children (BMI >85th percentile for 
age and sex, weight for height >85th percentile, or 
weight >120% of ideal for height) plus with any two 
of the following risk factors:
l  Family history of type 2 diabetes in first- or 
 second-degree relative
l  Race/ethnicity (Native American, African Ameri
 can, Latino, Asian American, Pacific Islander)
l  Signs of insulin resistance or conditions 
 associated with insulin resistance (acanthosis 
 nigricans, hypertension, dyslipidemia, polycystic 
 ovary syndrome, or small-for-gestational-age 
 birth weight)
l  Maternal history of diabetes or GDM during the 
 child’s gestation
When to Screen? 10 years of age or at onset of pu-
berty.
How often to screen? If results are normal, testing 
should be repeated at a minimum of 3-year intervals.
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Criteria For Screening For GDM 
An association between several maternal-fetal out-
comes and the level of maternal hyperglycemia has 
been reported hence screening for GDM is essential 
in every pregnancy. 
High risk group for GDM
l Strong family history of diabetes
l Prior history of GDM
l Morbid obesity
l Other manifestations of glucose intolerance
How to Screen? 2-h Plasma Glucose after 75-g 
OGTT
When to Screen?
l At the 1st prenatal visit in those with risk factors. 
l At 24–28 weeks of gestation in women not 
 previously known to have diabetes. 
l Screen women with GDM for persistent diabetes 
 at 4–12 weeks postpartum, using the OGTT. 
How often to screen? Women with GDM history 
should have lifelong screening for development of 
diabetes or pre-diabetes at least every 3 years.
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